$THC

MARK RICHARD J sold (to issuer) $86K of THC

MARK RICHARD J sold (to issuer) 493 shares of TENET HEALTHCARE CORP (THC) at $173.78 on 2026-05-22.

Original reporting
SEC EDGAR · MARK RICHARD J
Published May 27, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around management confidence, but without accompanying company fundamentals (earnings, guidance, litigation, contracts), the expected impact is limited.

02

Market read

A single insider sale disclosure for THC, with modest sentiment sensitivity due to non-10b5-1 labeling, but no fundamental catalyst mentioned.

03

What to watch

The absence of a 10b5-1 plan can increase perceived signal, but the article lacks context on why the sale occurred (tax, diversification, or corporate buyback participation).

Relevance 6/10Timing: Immediate (filed 2026-05-26; trade dated 2026-05-22) but typically limited follow-through.

Background

SEC Form 4 reports insider transactions by directors/officers; this filing shows a director sale to the issuer at a specific price and date.

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare director Mark Richard J sold 493 shares to the issuer for $173.78/share, disclosed via SEC Form 4 on 2026-05-26.

Expected impact

Low near-term impact; any reaction is likely limited to intraday sentiment around insider activity.

Evidence & confidence

The filing provides transaction size, price, and that it was not under a pre-arranged 10b5-1 plan, but it does not cite earnings, guidance, or operational changes.

Market effects

Minimal—no sector-wide catalyst is described beyond a single-company insider transaction.

None indicated; the filing is company-specific.

None indicated; no international or cross-border transaction details are provided.

Counterpoint

Because the sale is coded as “sale to issuer,” it may reflect routine liquidity/plan mechanics tied to corporate actions rather than a bearish view.

Key entities

  • Tenet Healthcare Corp

    Company whose director insider transaction was disclosed on SEC Form 4 (THC).

  • Mark Richard J

    Director who sold 493 shares to the issuer for $85,673.54; trade not stated as 10b5-1.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$THCMed

Tenet Healthcare (THC) Refinances Debt On A Fair Value Story That Looks Tightly Priced

Tenet Healthcare (THC) issued $2b in 6.250% senior notes due 2034 to refinance existing debt. Its share price has risen 25.4% in 90 days and 29.7% year-to-date. The company's fair value is estimated at $260, slightly above its current price of $258.62. Management's cost-reduction efforts have lowered contract labor and certain analytics costs, but further margin expansion may be limited.

$THCMed

Can THC's Cash Flow Support Its Expanding Capital-Return Strategy?

Tenet Healthcare (THC) reported a 27.1% year-over-year increase in operating cash flow to $2.2B in H1 2026, raising its adjusted free cash flow guidance to $1.825B-$2.055B. The company spent $1.4B on share buybacks and increased its repurchase authorization by $2B. THC is balancing buybacks with growth investments, expecting $700M-$800M in capital spending. Peers UHS and HCA also reported significant buybacks and capital investments.

$THCMed

Is Tenet Healthcare Corporation (THC) A Solid Play on Expanding Ambulatory Business?

Tenet Healthcare (THC) is focusing on its ambulatory business for growth, with BMO Capital Markets noting favorable long-term trends and margins. USPI, Tenet’s ambulatory platform, reported 9.3% revenue growth in Q2. BMO initiated coverage with a Market Perform rating and $265 price target. Hedge funds increased stakes, while short interest declined. Risks include reimbursement changes and competition.

$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2 Billion Debt Refinance Means For Shareholders

Tenet Healthcare (THC) completed a $2 billion private placement of senior unsecured notes due 2034 at a 6.250% coupon. Proceeds will redeem $1.5 billion of 2027 secured notes and $0.5 billion of 2028 senior notes, altering its capital structure and interest obligations. Analysts project revenues of $24.1 billion and earnings of $1.6 billion by 2029, with some seeing potential upside.

$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2b Debt Refinance Means For Shareholders

Tenet Healthcare (THC) priced a $2.0 billion private placement of 6.250% senior notes due 2034, upsized from $1.5 billion, to refinance existing 2027 and 2028 debt. The refinancing replaces secured and partly secured borrowings with unsecured notes, altering the company's debt structure. Investors focus on execution, pricing, and free cash flow, with high debt and earnings declines noted as risks.